SecBot SecBot

Cap Insulin Prices Act

S. 146 Sen. Josh Hawley (R-MO) In committee
Bill text PDF
  1. Introduced Jan 30
  2. Committee Jan 30
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jan 30, 2023Next: Senate vote
868d ago Jun 12, 2024: Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Subscribe to see spend
Member trades
3trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Financials 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Cap Insulin Prices Act

Full summary3 paragraphs

This bill reduces cost-sharing for insulin under private health insurance and the Medicare prescription drug benefit.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $25 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2024.

The bill caps cost-sharing under the Medicare prescription drug benefit for a month's supply insulin products at $25 beginning in 2024. The current cap on insulin products under Medicare is $35 per month.

Library of Congress summary, Jan 30, 2023

Summary versions
  • Introduced in SenateJan 30, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.